ArticleFrontiers in endocrinology2025
Analysis of the clinical characteristics of bone metastases after pheochromocytoma/paraganglioma surgery.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pheochromocytomas and paragangliomas (PPGLs) frequently metastasize to bone. We aimed to investigate the clinical characteristics of PPGL patients with postoperative bone metastases (BMs) in hopes of providing valuable insights into future clinical practices for patients with PPGLs. Methods: In this retrospective study, 107 patients were enrolled. The clinical, pathological and laboratory examination results of the patients were analyzed. We statistically investigated the clinical characteristics of BMs in PPGLs. Logistic regression analysis was used to determine the factors influencing BMs, and a Cox proportional hazards regression model was used to evaluate the prognostic factors of bone metastasis-free survival (BMFS) in patients with PPGLs. Results: Eighty-one of the 107 patients (75.7%) developed BMs, and BMs occurred at a median of 60 months after complete resection of the primary mass (range, 3-308 months). Most bone lesions were multiple (54 patients [66.7%]), and the spine was the most frequent site of bone involvement (229 lesions [63.3%]). Skeletal complications occurred in 31 patients (38.3%), of whom bone pain was the most common symptom (90.3%). Fifty-eight patients were grouped according to whether they had bone metastases or not. Logistic regression analysis revealed that SDHB mutation (OR Conclusions: PPGLs exhibit a pronounced tropism for bone, metastasizing to the skeletal system with higher frequency than to organs like the liver or lungs. These bone metastases are frequently associated with skeletal complications. SDHB mutation is a risk factor for bone metastases in PPGLs. It is crucial to emphasize genetic detection and postoperative follow-up examinations in patients with PPGLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.